Loading...
NeuroSense Therapeutics Ltd.
NRSNW•NASDAQ
Healthcare
Biotechnology
$0.85
$0.07(8.97%)
NeuroSense Therapeutics Ltd. (NRSNW) Stock Overview
Explore NeuroSense Therapeutics Ltd.’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for NRSNWStats details for NRSNW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for NRSNWAnalyst Recommendations details for NRSNW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
CEO
Mr. Alon Ben-Noon
Employees
17
Headquarters
Medinat ha-Yehudim Street 85, Herzliya
Founded
1970